Andrea Forschner, First Author; Saskia Biskup, Senior Author – “Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic #melanoma – results of a prospective biomarker study” https://t.co/ZM2NgwelEg @CeGaT_
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. https://t.co/AzE3j5q0Rt
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. https://t.co/5ZIyuwmZCd https://t.co/KTrw731Tl7
An interesting read by Forschner et al. on a prospctive biomarker study on TMB and ctDNA in combined antibody therapy in metastatic melanoma. https://t.co/DH30CcQ7cc
RT @sitcancer: New #JITC Research: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastat…
RT @sitcancer: New #JITC Research: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastat…
RT @tsemiglazovaMD: High #TMB , > 50% decrease of cell-free DNA concentration, & undetectable #ctDNA at 3 weeks after treatment initiation…
RT @tsemiglazovaMD: High #TMB , > 50% decrease of cell-free DNA concentration, & undetectable #ctDNA at 3 weeks after treatment initiation…
@OncoAlert
RT @tsemiglazovaMD: High #TMB , > 50% decrease of cell-free DNA concentration, & undetectable #ctDNA at 3 weeks after treatment initiation…
RT @tsemiglazovaMD: High #TMB , > 50% decrease of cell-free DNA concentration, & undetectable #ctDNA at 3 weeks after treatment initiation…
High #TMB , > 50% decrease of cell-free DNA concentration, & undetectable #ctDNA at 3 weeks after treatment initiation seem to be associated with response & OS under combined immunotherapy. #jitc #OncoAlert #niioncologii
RT @sitcancer: New #JITC Research: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastat…
New #JITC Research: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study https://t.co/UOjVfCMl3v https://t.co/cSlqmO5USW
RT @BeckiLee: Nice prospective study looking at tumor mutation burden and circulating tumor DNA as biomarkers of response to combo anti CTL…
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. https://t.co/WPSUd1oNQO
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. https://t.co/dneHiDwv7m
RT @ingentium_mel: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic #melanoma - r…
Nice prospective study looking at tumor mutation burden and circulating tumor DNA as biomarkers of response to combo anti CTLA-4 + PD-1 therapy in metastatic melanoma https://t.co/cqOQtkDNEQ
RT @ingentium_mel: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic #melanoma - r…
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic #melanoma - results of a prospective #biomarker study. https://t.co/Hfdd4AGj84